Stephen Rocamboli

Stephen Rocamboli is a declared insider at 3 companies (board member); the most frequent names are TFF Pharmaceuticals, Inc., Esperion Therapeutics, Inc. and VioQuest Pharmaceuticals, Inc. Between 14 January 2008 and 29 May 2025, the trades on record add up to 16 filings.

The open-market side counts 5 purchases for €40k alongside 3 sales for €764k. Taken together, the sales exceed the purchases by €724k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 4 share grants and 4 option exercises.

Half of the purchases are above €9,856 and half below. 4 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 2 June 2025, the filings show a share grant in Esperion Therapeutics, Inc. The most recent open-market purchase was published on 15 August 2023, 1,166 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.